Specific inhibition of a human papillomavirus E2 trans-activator by intracellular delivery of its repressor.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Specific inhibition of a human papillomavirus E2 trans-activator by intracellular delivery of its repressor.

DNA Cell Biol. 1994 Oct;13(10):1011-9. Unique Identifier : AIDSLINE MED/95032731
Pepinsky RB; Androphy EJ; Corina K; Brown R; Barsoum J; Biogen, Inc., Cambridge, MA 02142.

Abstract: Papillomaviruses are the causative agents of benign and malignant epithelial tumors of the skin and mucosa. They encode a DNA-binding protein, E2, that regulates viral transcription and replication, making it an important therapeutic target. By deleting the amino-terminal trans-activation domain of human papillomavirus type 16 (HPV-16) E2 while retaining its carboxy-terminal DNA binding and dimerization domain, an E2 repressor (E2R) that efficiently inhibits transcriptional activation by full-length HPV E2 was generated. To deliver this repressor protein into animal cells, we have utilized the human immunodeficiency virus type 1 (HIV-1) Tat protein which itself is taken up efficiently into intact cells. Chimeras of E2R and the cellular uptake domain of Tat specifically inhibited E2-dependent reporter gene expression in COS-7 cells. Treatment of cervical intraepithelial neoplasia cells having episomally replicating HPV-31 DNA with this Tat-E2R protein led to a dose-dependent loss of HPV DNA copies and inhibition of cell growth. Tat-mediated delivery can be a valuable tool for assessing protein function and may allow the development of novel therapeutic proteins having intracellular targets.

Keywords: Amino Acid Sequence Animal Base Sequence Cell Line Cervical Intraepithelial Neoplasia DNA, Viral Gene Products, tat/METABOLISM Molecular Sequence Data Oncogene Proteins, Viral/*METABOLISM Papillomavirus, Human/*GENETICS Repressor Proteins/*METABOLISM Trans-Activators/*ANTAGONISTS & INHIB Tumor Cells, Cultured JOURNAL ARTICLE
950228
M9521029

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .